Table 1.

Tumor PAM50 subtypes in the Nurses’ Health Study (NHS)/NHSII cohorts.

	Luminal A	Luminal B	HER2-Enriched	Basal-like	Normal-like
n	405	157	124	128	68
NHS Cohort, n (%)
NHS	234 (57.8)	93 (59.2)	81 (65.3)	84 (65.6)	45 (66.2)
NHSII	171 (42.2)	64 (40.8)	43 (34.7)	44 (34.4)	23 (33.8)
Tumor grade, n (%)
1: Predominantly well-differentiated	143 (36.4)	21 (13.5)	14 (11.8)	11 (9.4)	22 (36.1)
2: Moderately differentiated	216 (55.0)	86 (55.1)	72 (60.5)	33 (28.2)	35 (57.4)
3: Poorly differentiated	34 (8.7)	49 (31.4)	33 (27.7)	73 (62.4)	4 (6.6)
Stage, n (%)
I	265 (65.6)	89 (56.7)	65 (52.4)	62 (48.8)	47 (69.1)
II	104 (25.7)	53 (33.8)	40 (32.3)	59 (46.5)	15 (22.1)
III	32 (7.9)	14 (8.9)	18 (14.5)	6 (4.7)	5 (7.4)
IV	3 (0.7)	1 (0.6)	1 (0.8)	0 (0.0)	1 (1.5)
Tumor estrogen receptor, n (%)
Positive	389 (96.5)	150 (96.2)	82 (66.7)	36 (28.3)	52 (76.5)
Negative	14 (3.5)	6 (3.8)	41 (33.3)	91 (71.7)	16 (23.5)
Tumor progesterone receptor, n (%)
Positive	382 (95.3)	141 (90.4)	76 (62.3)	33 (26.2)	51 (75.0)
Negative	19 (4.7)	15 (9.6)	46 (37.7)	93 (73.8)	17 (25.0)
Tumor HER2, n (%)
Positive	101 (26.5)	40 (27.8)	48 (42.1)	21 (17.8)	14 (23.0)
Negative	280 (73.5)	104 (72.2)	66 (57.9)	97 (82.2)	47 (77.0)
Tumor Ki-67, n (%)
High	36 (25.2)	27 (44.3)	19 (38.0)	26 (49.1)	5 (16.7)
Low	107 (74.8)	34 (55.7)	31 (62.0)	27 (50.9)	25 (83.3)